Impact of prior seasonal influenza vaccination and infection on pandemic A (H1N1) influenza virus replication in ferrets

A.H. Ellebedy, M.F. Ducatez, S. Duan, E. Stigger-Rosser, A.M. Rubrum, E.A. Govorkova, R.G. Webster, R.J. Webby

Department of Infectious Diseases, St. Jude Children’s Research Hospital, 262 Danny Thomas Place, Memphis, TN 38105-3678, USA

Abstract

Early epidemiologic and serologic studies have suggested pre-existing immunity to the pandemic A (H1N1) 2009 influenza virus (H1N1pdm) may be altering its morbidity and mortality in humans. To determine the role that contemporary seasonal H1N1 virus infection or trivalent inactivated vaccine (TIV) might be playing in this immunity we conducted a vaccination-challenge study in ferrets. Vaccination with TIV was unable to alter subsequent morbidity or contact transmission in ferrets following challenge with H1N1pdm. Conversely, prior infection with the contemporary seasonal H1N1 strain altered morbidity, but not transmission, of H1N1pdm despite the detection of only minimal levels of cross reactive antibodies.

© 2010 Elsevier Ltd. All rights reserved.

1. Introduction

The emergence of the H1N1pdm virus is a serious global public health concern [1]. Preliminary analysis of early virus isolates showed that they possess 6 gene segments phylogenetically related to those of triple-reassortant viruses known to circulate in swine in North America and Asia and 2 genes (neuraminidase and matrix) related to those of influenza A viruses circulating in the Eurasian swine population [2]. The virus has spread globally leading to the first influenza pandemic of the 21st century.

Although animal models suggest that H1N1pdm viruses are intrinsically more pathogenic than contemporary seasonal human H1N1 strains [3–5], clinical observations show that both strains have similar pathogenicities in humans in most age groups [6]. This disparity between animal models and humans could be explained by a degree of existing immunity in humans to the pandemic strain. Indeed, the hemagglutinin (HA) gene ancestral to the pandemic and seasonal H1 strains is that which entered humans and swine during the 1918 influenza pandemic. Consistent with an impact of pre-existing immunity are serologic studies that have shown an age dependent level of H1N1pdm-neutralizing antibody in humans [3,7]. This data from clinical studies remains ambiguous in terms of the impact of TIV on H1N1pdm in humans. Two such studies, a case-cohort study in the US and a case–control study in Australia have concluded that prior TIV administration had no protective effects on H1N1pdm [15,16]. Conversely, a case–control and a retrospective-cohort study conducted in Mexico have both found a protective capacity for TIV, especially against the severe forms of H1N1pdm induced disease [17,18]. Moreover, Del Giudice et al. showed that in ferrets TIV administration immunologically prime for a better antibody response against the H1N1pdm monovalent vaccine [19]. Finally, a recently published Canadian study showed that prior recipients of the 2008–2009 TIV were approximately twice as susceptible to developing illness following H1N1pdm infection compared to those who had not received the vaccine [20].
TIV or prior seasonal H1N1 infection influences the pathogenicity and transmission of the pandemic virus is poorly understood. The focus of this study was therefore to determine whether prior vaccination against or exposure to seasonal H1N1 virus could alter subsequent replication of a H1N1pdm virus in ferrets.

2. Methods

2.1. Viruses and cells

The H1N1 viruses A/Brisbane/59/2007 (contemporary seasonal vaccine strain, passaged three times in eggs and twice in MDCK cells before being used), A/Tennessee/1-560/2009 (a representative H1N1pdm strain, pasaged three times in eggs before being used), and the A/California/07/2009 vaccine strain (H1N1pdm virus, rescued in eggs) were obtained from the World Health Organization influenza-collaborating laboratories. MDCK cells were obtained from the American Type Culture Collection (Manassas, VA) and were grown in a humidified atmosphere of 5% CO2 at 37 °C. MDCK cells were obtained from the World Health Organization influenza-collaborating laboratories. MDCK cells were obtained from the American Type Culture Collection (Manassas, VA) and were grown in a humidified atmosphere of 5% CO2 at 37 °C.

2.2. Ferrets

Young male and female ferrets 3–4 months of age and seronegative for currently circulating influenza A H1N1, H3N2, and influenza B viruses were obtained from Triple F farms (Sayre, PA) and from the breeding program at the St Jude Children’s Research Hospital. All animal experiments were performed in a biosafety level 2 laboratory, using biosafety level 3 practices. All animal experiments were approved by the Animal Care and Use Committee of St. Jude and performed in compliance with relevant institutional policies of the National Institutes of Health regulation and the Animal Welfare Act. A subcutaneous implantable temperature transponder (Bio Medic Data Systems, Inc., Seaford, DE) was placed in each ferret for identification and to take temperature readings.

2.3. Immunization and challenge

To mimic several possible scenarios of how prior TIV administration or A/Brisbane/59/2007 (H1N1) infection might affect the pathogenicity and spread of A/Tennessee/1-560/2009 (H1N1), we included a number of experimental groups in our study. Animals were divided into 4 groups, with 4 ferrets per group. Group 1 received two 15 μg doses of the 2008–2009 northern hemisphere seasonal TIV (Fluzone, Sanofi Pasteur, Swift water, PA) in the form of intramuscular injection, at a 3-week interval to mimic the form of intramuscular injection, at a 3-week interval to mimic the likely pandemic dosing schedule in naive individuals. Group 2 was intranasally infected with 10^6 50% egg infectious doses (EID50) in a 1 mL inoculum volume of live A/Brisbane/59/2007 (H1N1) (the current H1N1 component of the vaccine) and vaccinated 3 weeks later with the seasonal vaccine to mimic the scenario of exposure followed by vaccination. Group 3 received a dose of PBS followed 3 weeks later by a single dose of TIV. Group 4 received 2 doses of phosphate-buffered saline (PBS) as a control. Three weeks after the second immunization, all animals were challenged intranasally with 10^6 EID50 of A/Tennessee/1-560/2009 (H1N1) in a 1 mL inoculum volume, a representative pandemic strain. As a benchmark control, two additional groups of 4 ferrets were included: Group 5 was vaccinated twice at a 3-weeks interval with the seasonal TIV and Group 6 mock-vaccinated twice with PBS. Both groups were subsequently challenged intranasally in a 1 mL inoculum volume with 10^6 EID50 of the contemporary seasonal strain A/Brisbane/59/2007 (H1N1). Challenged ferrets were then monitored daily for 10 days for weight change, temperature and clinical disease signs. Body temperature was measured via transponders subcutaneously implanted between the shoulder blades (BioMedic Data Systems, Inc., Seaford, DE).

2.4. Transmission studies

For each of the vaccine groups described above, two ferrets were used for evaluation of viral contact transmission. Twenty-four hours after challenge, a naïve ferret was introduced into the cage housing an inoculated ferret (two contact/infected animal pairs per group). Male and female ferrets were used in the transmission arm of the study but we did not observe any difference in the pattern of virus transmission among these ferrets.

2.5. Nasal washes

On days 2, 4, 7, and 9 after virus inoculation, ferrets were anesthetized with ketamine (25 mg/kg), and 0.5 mL of PBS with antibiotics was slowly introduced into each nostril, recovered, measured, and brought to a volume of 1.0 mL with sterile PBS containing antibiotics. Bovine serum albumin 7.5% was added at a ratio of 1:20 (v/v) as a stabilizing agent. Virus was titrated in eggs and expressed as log10 EID50/mL [21]. The limit of virus detection was <0.75 log10 EID50/mL. Virus titers were compared by an ANOVA test, and when appropriate, Tukey’s multiple comparison test.

2.6. Serologic testing

Serum ferret sera were obtained before vaccination or infection, before vaccine boost, before challenge, and 10 days after challenge. Serum samples were treated with receptor-destroying enzyme (Accurate Chemicals and Scientific, New York) overnight at 37 °C, heat-inactivated at 56 °C for 30 min, and diluted 1:10 in PBS and tested by the hemagglutination inhibition (HI) assay with 0.5% packed turkey red blood cells. Virus-neutralizing antibody titers were determined in MDCK cells. Briefly, the 50% tissue culture infectious dose (TCID50) was determined for each virus used, and 2-fold serial dilutions of serum were incubated with 100 TCID50 of virus for 1 h at 37 °C. The mixture was then added to MDCK cells and incubated for 72 h at 37 °C in 5% CO2. After 72 h, HA activity of the supernatant was assessed by the HA assay with 0.5% packed turkey red blood cells. Neutralizing titers were expressed as the reciprocal of the serum dilution that inhibited 50% of the HA activity of 100 TCID50 of virus. Both HI and MN assays were performed with A/Brisbane/59/2007 and the A/California/07/2009 vaccine seed strain in a BSL2 + laboratory. For antigen-specific ELISA, microwell plates (Corning, Lowell, MA) were coated overnight at 4 °C with inactivated purified whole A/Brisbane/59/2007 or A/Tennessee/1-560/2009 viruses in PBS. After an overnight incubation with serial dilutions of ferrets’ sera, influenza-specific IgG antibodies were detected with a goat anti-ferret IgG alkaline-phosphatase conjugate (Biotrend, Cologne, Germany) diluted 1:1000 in PBS with 1% bovine serum albumin (BSA). The substrate (p-nitrophenyl phosphate; Sigma–Aldrich, Atlanta, GA) was added, plates were incubated for 30 min at room temperature for color development, and OD values were determined at 405 nm in an ELISA reader (Bio- rad, Los Angeles, CA).

3. Results

3.1. Impact of TIV or prior infection on H1N1pdm replication in ferrets

To determine the effect of prior priming scenarios on subsequent A/Tennessee/1-560/2009 (H1N1) replication, a number of
Although vaccination with TIV alone did not have a significant impact on A/Tennessee/1-560/2009 (H1N1) disease progression in ferrets. These results were consistent with the lack of detectable serum-neutralizing antibodies generated by the TIV that were able to inhibit the pandemic strain, as measured by hemagglutination inhibition (HI) or microneutralization (MN), although non-neutralizing antibodies were detected by ELISA (Table 1). A/Tennessee/1-560/2009 (H1N1) induced disease in ferrets that was characterized by fever, weight loss, sneezing, and viral clearance by day 7 post infection (Table 2) [3-5].

Vaccinated animals, despite the lack of detectable cross-reacting antibodies prior to challenge (Fig. 1 and Table 1). Correspondingly, Group 2 ferrets pre-infected with A/Brisbane/59/2009 (H1N1) then vaccinated with TIV recovered faster than ferrets in other groups; ferrets in Group 2 started gaining weight as early as day 5 or 6 post infection whereas those in Groups 1, 3, and 4 did not recover until day 8 or 9 post infection (Fig. 2).

### 3.2. Impact of TIV on A/Brisbane/59/2007 (H1N1) replication in ferrets

To be able to put the effect of TIV administration on H1N1pdm replication into context, we also infected TIV dosed ferrets with A/Brisbane/59/2009 (H1N1), a component of the TIV. Somewhat surprisingly, the vaccine had only a minor protective capacity. Although TIV decreased subsequent A/Brisbane/59/2007 (H1N1) replication in the upper respiratory tract of vaccinated ferrets (Group 5) at day 2 post infection, the reduction did not reach significance in comparison to control animals (Group 6); P = 0.0528 (Fig. 3). There were no other detectable differences between Group 5 and 6 challenged animals in terms of weight loss or clinical signs.

### Table 1
Serum antibody titers against the seasonal and pandemic H1N1 viruses.

<table>
<thead>
<tr>
<th>Ferret group</th>
<th>Vaccine regimen</th>
<th>Challenge virus</th>
<th>Titters against A/Brisbane/59/2007 (H1N1)*</th>
<th>Titters against the 2009 pandemic H1N1*</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>A/Tennessee/1-560/2009</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>Two doses of the 2008/09 TIV</td>
<td>A/Tennessee/1-560/2009</td>
<td>22.5 (35)</td>
<td>MN, mean (IgG), mean</td>
</tr>
<tr>
<td>2</td>
<td>Infection then vaccination</td>
<td>A/Tennessee/1-560/2009</td>
<td>&gt; 800 (960)</td>
<td>&lt; 100</td>
</tr>
<tr>
<td>3</td>
<td>Single dose of the 2008/09 TIV</td>
<td>A/Tennessee/1-560/2009</td>
<td>13.75 (35)</td>
<td>MN, mean (IgG), mean</td>
</tr>
<tr>
<td>4</td>
<td>PBS</td>
<td>A/Tennessee/1-560/2009</td>
<td>&lt; 10</td>
<td>MN, mean (IgG), mean</td>
</tr>
<tr>
<td>5</td>
<td>Two doses of the 2008/09 TIV</td>
<td>A/Brisbane/59/2007</td>
<td>38.75 (75)</td>
<td>MN, mean (IgG), mean</td>
</tr>
<tr>
<td>6</td>
<td>PBS</td>
<td>A/Brisbane/59/2007</td>
<td>&lt; 10</td>
<td>MN, mean (IgG), mean</td>
</tr>
</tbody>
</table>

*These are the titer of the serum samples collected prior to challenge.

**For ferrets that received 2 doses, the vaccinations were administered 3 weeks apart.

***The challenge occurred 3 weeks after the vaccination boost, challenge dose of live virus: 10^6 EID_{50} for each ferret.

### Fig. 1
Shedding of influenza virus A/Tennessee/1-560/2009 (H1N1) in ferrets. Nasal washes were collected on days 2, 4, 7 and 9 post challenge for inoculated ferrets and on days 3, 6, and 8 post contact for naive contact animals. Virus titers were determined by end-point titration in embryonated chicken eggs. Arithmetic mean titers are given; error bars indicate standard error. The black, red, blue and yellow curves represent the titers of groups 1, 2, 3, and 4 respectively.

### Fig. 2
Weight loss of A/Tennessee/1-560/2009 inoculated ferrets. The black, red, blue and yellow curves represent the titers of groups 1, 2, 3 and 4 respectively.
we did not observe any significant differences in the serologic titers between the pandemic virus in animals that were infected with the seasonal H1N1 viruses prior to and after receiving the seasonal vaccine. Although a specific vaccine is highly recommended for vaccine-induced protection, our data suggest that a higher proportion of the population will have basal levels of pre-existing immunity to the novel strain than suggested by prior serologic studies [3,7]. These studies demonstrated that the detectable antibody cross-reactivity’s to H1N1pdm viruses is seen only in those individuals alive during the early stages of the 1918 influenza pandemic. The absence of detectable neutralizing antibodies against H1N1pdm after seasonal virus infection in our study is consistent with the results of these investigators; the subsequent protection seen in ferrets, however, is somewhat more encouraging from a public health standpoint and indicates that human serology underestimates the degree of existing H1N1pdm immunity. Although protection in the absence of detectable neutralizing antibody titers is not without precedent, it does raise questions as to the mechanisms involved. Three, by no means mutually exclusive, possible mechanisms are protection mediated by non-neutralizing antibodies (as detected by ELISA, Table 1), neutralizing antibodies below the assay detection thresholds, or cross-reactive memory CD8 T-cells. A recent computer search has indeed shown conservation of a number of known CD8+ T cell epitopes between seasonal and pandemic H1N1 strains [22,23]. Data comparing the efficacy of live attenuated and TIV formulations of H1N1pdm may provide additional information as to the role of T cell mediated immune mechanism in the modulation of disease associated with the current pandemic.

Although the A/Brisbane/59/2007 driven cross immunity in the ferret model was not particularly potent, its effects at a population level in humans may be significant. It is also worth noting that we were only able to test transmission in a contact model and that the impact of previous exposures could be more substantial on droplet transmission. In terms of pandemic vaccination, it is encouraging to see that control and contact ferrets challenged with A/Tennessee/1-560/2009 were able to generate a faster and higher antibody response than their A/Brisbane/59/2007 counterparts (Table 2), suggesting that a human H1N1pdm vaccine may not have the poor immunogenicity seen in unadjuvanted H5N1 vaccines [24], a finding supported by recent clinical trial data [25,26]. These data show that, unlike pre-trial predictions, a single 15 μg dose of monovalent H1N1pdm vaccine was enough to elicit a sero-protective response (H ≥ 40) in over 90% of people in both trials. This result is in contrast to H5 and H9 vaccine trials which showed disappointing levels of immunogenicity with unadjuvanted vaccines [24,27] and suggests that a majority of the population has been primed against the H1N1pdm vaccine to some degree. The ability of A/Brisbane/59/2007 to provide some protection against

### Table 2

| Clinical signs of inoculated and direct contact ferrets. |
|-----------------|-----------------|-----------------|-----------------|-----------------|
| Group | Challenge or contact virus | Weight loss (%)<sup>a</sup> | Fever<sup>b</sup> | Sneezing<sup>c</sup> | Lethality | Virus shedding<sup>d</sup> | Last day of shedding<sup>e</sup> | Sero-conversion<sup>f</sup> | Direct contact animals |
|---|----------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|
| 3 | 4/4 (7.3) | 4/4 | 4/4 | 0/4 | 4/4 (5.5) | <7 | 4/4 (>4) | 4/4 (3.4) | 4/4 (>4) |
| 5 | 4/4 (6.2) | 2/4 | 3/4 | 0/4 | 4/4 (5.7) | <9 | 4/4 (>4) | 4/4 (7.5) | 4/4 (w) |
| 6 | 4/4 (5.0) | 3/4 | 3/4 | 0/4 | 4/4 (6.6) | <9 | 4/4 (>4) | 4/4 (7.4) | 4/4 (w) |

<sup>a</sup>Mean maximum percentage weight loss post challenge (as compared to weight at challenge day).

<sup>b</sup>A temperature increase of ≥0.7 °C above day 0 temperature was considered as a fever.

<sup>c</sup>Number of ferrets observed sneezing during the 10 days after challenge.

<sup>d</sup>Titers were measured in nasal washes. The mean peak value per group is indicated in parentheses, expressed in $\log_{10}$ EID50/mL.

<sup>e</sup><x= indicates that at day x the ferrets were not shedding virus any longer.

<sup>f</sup>Seroconversion was observed against the challenge (or contact) virus both by HI and MN assays. The mean arithmetic MN titer per group is indicated in parentheses; w stands for weak titers (<10 in HI and <70 in MN assay) and > for high titers (≥1280 in HI and ≥130 in MN assays).
A/Tennessee/1-560/2009 in our experiments suggests that the seasonal H1N1 strains may be providing this priming. Future animal studies with the pandemic vaccine will help to confirm this.

A somewhat unexpected finding in this study was the relative ineffectiveness of TIV in protecting from the homologous A/Brisbane/59/2007 challenge. Although there was a slight reduction in nasal shedding in vaccinated versus control animals at some time points, there was no significant difference in weight loss or transmission between groups. The lack of efficacy was not due to an absence of a response to the vaccine as seroprotective titers were observed in 2 of 4 ferrets; the remaining 2 ferrets had HI titers of 30 and <10. This result raises the issue of the suitability of the ferret for modeling the human response to TIV. Thus, it is quite possible that TIV administration in a naive host has marginal efficacy against virus replication, particularly for virus with tropism for the upper airways, and that what we have observed in ferrets is a true representation of what is seen in humans.

Taken together our data provide evidence for a negligible role for seasonal TIV which is consistent with what Del Giudice et al. has shown [19], but not prior H1N1 infection, in altering H1N1pdm disease and transmission.

Acknowledgments

We gratefully acknowledge Heather Forrest, Patrick Seiler, Sharon Lokey, David Carey, Angela Ferguson, and Scott Krauss for their excellent technical assistance, Vani Shanker for editorial assistance. We thank the WHO Global Influenza Surveillance Network for providing the H1N1 viruses and the US National Institute of Allergy and Infectious Diseases (NIAID) for provision of TIV. This study was partially supported by the NIAID (contract no. HHSN266200700005C), the American Lebanese Syrian Associated Charities.

Conflict of interest statement: None declared. The corresponding author has had full access to all the data in the study and has had the final responsibility for the decision to submit this manuscript for publication.

Funding: NIH NIHMS-ID: 234984.

References